Clonal Heterogeneity in Urothelial Cancer
Bishoy Faltas, MD, clinical fellow, Weill Cornell Medical College, discusses clonal heterogeneity in platinum-resistant metastatic urothelial cancer.
Clinical Pearls
Bishoy Faltas, MD, clinical fellow, Weill Cornell Medical College, discussesclonal heterogeneity in platinum-resistant metastatic urothelial cancer.
- This study found a significant degree of both inter- and intra-patient heterogeneity.
- There were differences in the patterns of evolution of molecular alterations in these samples.
- Subclonal mutations went on to be enriched in and constitute most mutations in metastatic samples.
- Mutations in primary samples were identified that were not enriched in metastatic samples.
- It was found that the metastatic samples continued to change even after evolving from the primary tumor samples.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
